Literature DB >> 11222568

Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada.

K Weiss1, J De Azavedo, C Restieri, L A Galarneau, M Gourdeau, P Harvey, J F Paradis, K Salim, D E Low.   

Abstract

Resistance to macrolides among group A streptococci is an increasing problem worldwide. We examined 496 strains phenotypically and genotypically for resistance to erythromycin and clindamycin. Strains were isolated in five different geographical areas representing about 45% of the total Quebec population. The overall resistance rate was 4.6% but varied from 0% in rural areas to 9.4% in Montreal. Of the 23 strains showing resistance to erythromycin, 15 (65%) had an identical pulsed-field gel electrophoresis pattern, were of serotype M28T28 and harboured the erm(TR) gene, suggesting the spread of a single clone. Of the remaining eight strains, two strains had the erm(B) gene, five had the mef gene and one with a different serotype also had the erm(TR) gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222568     DOI: 10.1093/jac/47.3.345

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Epidemiologic analysis of invasive and noninvasive group a streptococcal isolates in Hong Kong.

Authors:  P L Ho; D R Johnson; A W Y Yue; D N C Tsang; T L Que; B Beall; E L Kaplan
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

2.  Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002).

Authors:  Gregory J Tyrrell; Marguerite Lovgren; Bertha Kress; Karen Grimsrud
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 3.  Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).

Authors:  Corné H W Klaassen; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Macrolide-resistant Streptococcus pyogenes in Norway: population structure and resistance determinants.

Authors:  P Littauer; D A Caugant; M Sangvik; E A Høiby; A Sundsfjord; G S Simonsen
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy.

Authors:  Giordano Dicuonzo; Ersilia Fiscarelli; Giovanni Gherardi; Giulia Lorino; Fabrizio Battistoni; Simona Landi; Marina De Cesaris; Tommasangelo Petitti; Bernard Beall
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Emergence of macrolide-resistant Streptococcus pyogenes strains in French children.

Authors:  Edouard Bingen; Philippe Bidet; Liliana Mihaila-Amrouche; Catherine Doit; Samuel Forcet; Naïma Brahimi; Anne Bouvet; Robert Cohen
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area.

Authors:  Meredith E Hasenbein; John E Warner; Kathleen G Lambert; Sarah E Cole; Andrew B Onderdonk; Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

9.  Erythromycin resistance in Streptococcus pyogenes and macrolide consumption in a central Italian region.

Authors:  F Montagnani; L Stolzuoli; L Croci; C Rizzuti; F Arena; A Zanchi; C Cellesi
Journal:  Infection       Date:  2008-12-05       Impact factor: 3.553

10.  Erythromycin-resistant group A streptococcal isolates recovered in Sofia, Bulgaria, from 1995 to 2001.

Authors:  Antoaneta Detcheva; Richard R Facklam; Bernard Beall
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.